These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

56 related articles for article (PubMed ID: 11362905)

  • 21. Viral load testing.
    Sax P; Flory J
    AIDS Clin Care; 1996 Apr; 8(4):31-2. PubMed ID: 11363258
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 23. New study on viral load.
    Posit Aware; 1996; 7(1):5. PubMed ID: 11363123
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of drug resistance genotypes on CD4+ counts and plasma viremia in heavily antiretroviral-experienced HIV-infected patients.
    Rodes B; García F; Gutierrez C; Martinez-Picado J; Aguilera A; Saumoy M; Vallejo A; Domingo P; Dalmau D; Ribas MA; Blanco JL; Pedreira J; Perez-Elias MJ; Leal M; de Mendoza C; Soriano V;
    J Med Virol; 2005 Sep; 77(1):23-8. PubMed ID: 16032728
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Diagnostic accuracy of CD4 cell count increase for virologic response after initiating highly active antiretroviral therapy.
    Bisson GP; Gross R; Strom JB; Rollins C; Bellamy S; Weinstein R; Friedman H; Dickinson D; Frank I; Strom BL; Gaolathe T; Ndwapi N
    AIDS; 2006 Aug; 20(12):1613-9. PubMed ID: 16868442
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term suppression of plasma viremia with highly active antiretroviral therapy despite virus evolution and very limited selection of drug-resistant genotypes.
    Pariente N; Pernas M; de la Rosa R; Gómez-Mariano G; Fernández G; Rubio A; López M; Benito JM; López-Galíndez C; Leal M; Domingo E; Martinez MA; Mas A
    J Med Virol; 2004 Jul; 73(3):350-61. PubMed ID: 15170628
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immune improvement in an HIV-infected man.
    AIDS Clin Care; 1996 Jul; 8(7):56, 62. PubMed ID: 11363602
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A longitudinal and prospective study of Epstein-Barr virus load in AIDS-related non-Hodgkin lymphoma.
    Bonnet F; Jouvencel AC; Parrens M; Leon MJ; Cotto E; Garrigue I; Morlat P; Beylot J; Fleury H; Lafon ME
    J Clin Virol; 2006 Aug; 36(4):258-63. PubMed ID: 16762591
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Piloting the meanders of AIDS research.
    Mascolini M
    J Int Assoc Physicians AIDS Care; 1996 Dec; 2(12):9-27. PubMed ID: 11363956
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An FDA-ok'd viral load test? The wait may be nearly over. Food and Drug Administration.
    Mascolini M
    J Int Assoc Physicians AIDS Care; 1996 Jan; 2(1):6-9. PubMed ID: 11363333
    [TBL] [Abstract][Full Text] [Related]  

  • 31. HIV surrogate markers: new virologic and immunologic indicators.
    MacDougall DS
    J Int Assoc Physicians AIDS Care; 1997 Mar; 3(3):15-7. PubMed ID: 11364123
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative performance of the Amplicor HIV-1 Monitor Assay versus NucliSens EasyQ in HIV subtype C-infected patients.
    Gottesman BS; Grossman Z; Lorber M; Levi I; Shitrit P; Katzir M; Shahar E; Gottesman G; Chowers M
    J Med Virol; 2006 Jul; 78(7):883-7. PubMed ID: 16721845
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Quantitative detection of human immunodeficiency virus type 1 (HIV-1) proviral DNA in peripheral blood mononuclear cells by SYBR green real-time PCR technique.
    Gibellini D; Vitone F; Schiavone P; Ponti C; La Placa M; Re MC
    J Clin Virol; 2004 Apr; 29(4):282-9. PubMed ID: 15018857
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Development of methods for coordinate measurement of total cell-associated and integrated human immunodeficiency virus type 1 (HIV-1) DNA forms in routine clinical samples: levels are not associated with clinical parameters, but low levels of integrated HIV-1 DNA may be prognostic for continued successful therapy.
    Carr JM; Cheney KM; Coolen C; Davis A; Shaw D; Ferguson W; Chang G; Higgins G; Burrell C; Li P
    J Clin Microbiol; 2007 Apr; 45(4):1288-97. PubMed ID: 17314225
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Detection and quantification of proviral HIV-1 184 M/V in circulating CD4(+) T cells of patients on HAART with a viremia less than 1,000 copies/ml.
    Mohey R; Jørgensen LB; Møller BK; Black FT; Kjems J; Obel N
    J Clin Virol; 2005 Dec; 34(4):257-67. PubMed ID: 16286049
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Predictive factors for immunological and virological endpoints in Thai patients receiving combination antiretroviral treatment.
    Srasuebkul P; Ungsedhapand C; Ruxrungtham K; Boyd MA; Phanuphak P; Cooper DA; Law MG
    HIV Med; 2007 Jan; 8(1):46-54. PubMed ID: 17305932
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparing RNA PCR tests.
    Cheng B
    PI Perspect; 1995 Dec; (no 17):15. PubMed ID: 11363106
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Viral measurement by polymerase chain reaction-based assays in human immunodeficiency virus-infected infants.
    Palumbo PE; Kwok S; Waters S; Wesley Y; Lewis D; McKinney N; Bardeguez A; Connor EM; Oleske JM
    J Pediatr; 1995 Apr; 126(4):592-5. PubMed ID: 7699539
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Viral load: new "strategy" trial in 15 U.S. cities.
    James JS
    AIDS Treat News; 1995 Oct; (no 233):1-3. PubMed ID: 11363037
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Viral load in symptomatic primary HIV-infection.
    Joubert L; Meyohas MC; Ollivier I; Frottier J; Petit JC; Mariotti M; Lefrère JJ
    AIDS; 1993 Aug; 7(8):1127-8. PubMed ID: 8397953
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.